2-hydroazono-1-adamantane acetic acids

ABSTRACT

ADAMANTANOPYRIDAZINE COMPOUNDS OF THE FORMULAE (1) 1,3,11-TRI(R-),6-R&#34;,7-(O=),8-R&#39;&#39;-6,7-DIHYDRO-8HADAMANTANO(3,4-E)PYRIDAZINE,   AND (11) 1,3,11-TRI(R-),6-R&#34;,8-R&#39;&#39;-PERHYDROADAMANTANO(3,4-E)PYRIDAZINE AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF THESE COMPOUNDS, THE INTERMEDIATES BEING OF THE FORMULA: (111) 3,5,7-TRI(R-),1-(HOOC-CH(-R&#39;&#39;)-),2-(R&#34;-NH-N=)ADAMANTANE THE ADAMANTANOPYRIDAZINE COMPOUNDS (FORMULAE 1 AND 11) ARE USEFUL AS ANTI-INFLAMMATORY AGENTS AND AS CNS DEPRESSANTS.

United States Patent O 3,766,262 Z-HYDROAZONO-l-ADAMANTANE ACETIC ACIDS Stephen Slomo Szinai, Wokingham, and Jiban Kumar Chakrabarti, Frimley, England, assignors to Eli Lilly and Company, Indianapolis, Ind.

No Drawing. Original application May 1, 1969, Ser. No. 821,078, now Patent No. 3,627,764. Divided and this application Apr. 5, 1971, Ser. No. 131,440

Int. Cl. C07c 109/14 US. Cl. 260-518 R 3 Claims ABSTRACT OF THE DISCLOSURE Adamantanopyridazine compounds of the formulae and and intermediates useful in the synthesis of these compounds, the intermediates being of the formula:

(III) The adamantanopyridazine compounds (Formulae I and II) are useful as anti-inflammatory agents and as CNS depressants.

3,766,262 Patented Oct. 16, 1973 CROSS REFERENCE TO RELATED APPLICATION This application is a divisional application of our copending application Ser. No. 821,078, filed May 1, 1969, now Pat. No. 3,627,764.

SUMMARY OF THE INVENTION The present invention is concerned with certain adamantanopyridazine compounds and with intermediates useful in their synthesis. The subject matter can more readily be understood by reference to the following summary reaction scheme and definitions:

In the formulae above, as well as throughout the present specification and claims, the symbol R represents hydrogen or loweralkyl of C -C both inclusive, the sum of the number of carbon atoms in all three R groups being not greater than 6; R represents hydrogen or straight-chain loweralkyl of C -C and R" represents hydrogen, loweralkyl of C -C hydroxyloweralkyl of C -C phenyl, or substituted phenyl of the formula wherein R" represents bromo, chloro, or methyl; m represents 03; and n represents 0-2, the sum of m and n being an integer of from 1 to 3; both inclusive.

DETAILED DESCRIPTION OF THE INVENTION Standard chemical nomenclature is employed herein. Thus, the starting materials and intermediates are named as derivatives of l-adamantaneacetic acids; and the ultimate products of the present invention, while generically referred to herein, for the sake of convenience, as adamentanopyridazine compounds, are individually named as derivatives of a tetracyclic structure identified as 5,6 diazatetracyclo(7.3.11 .0 )tetradecane.

As set forth above, the ultimate products of the present invention are prepared by a series of reactions.

The initial reaction is the reaction of a 2-ket0-l-adamantaneacetic acid:

with a substituted hydrazine of the formula:

NHz-NH-R" to yield the corresponding hydrazone intermediates:

RI a-a-on The reaction is conveniently carried out in an inert liquid reaction medium, such as, for example, one of the loweralkanols. The reaction goes forward when employing the reactants in any amounts; however, the reaction consumes the reactants in amounts representing equimolecular proportions and the use of the reactants in such amounts is preferred. The reaction goes forward under temperatures of a wide range, but is preferably conducted at temperatures of'from to 80 C. The reaction yields the desired hydrazone and water as by product. Ordinarily, the hydrazone precipitates in the reaction mixture and is conveniently separated by filtration; in any event, separation, and if desired, purification are conducted in conventional procedures.

The hydrazone intermediate thereby obtained is cyclized to obtain the corresponding product of the present invention:

where is thereafter reduced to obtain the corresponding product:

The cyclization can be effected by any of the various procedures known for the effecting of an intramolecular dehydration. Most conveniently, the hydrazone product is merely heated, as, for example, to temperatures of 175 to 250 C., in a suitable inert liquid reaction medium. In the instance of many of the hydrazones, excessive heating in the preparation of the hydrazone itself will results in cyclization. Therefore,to insure preparation of the hydrazone intermediate, where desired, heating should be controlled. In the cyclization reaction as .in the reaction preparing the. hydrazone intermediate, water is produced as a by-product. Separation and purification of the cyclic product are'carried out in conventional procedures.

The reduction is similarly carired out in procedures known in the prior art. Most preferably, the initial cyclic product is reacted with excess lithium aluminum hydride in suitable solvent, conveniently an ether such as dioxane. The reaction goes forward under temperatures of awide range, but is preferably conducted at temperatures of from 60 to 120 C. Separation and purification of the product are carried out in conventional procedures.

Compounds of Formulae I and II are readily reacted with suitable acids, such as hydrochloric acid, sulfuric acid and phosphoric acid, in standard procedures to obtain the corresponding acid addition salts. Particularly suited for the practice of the present invention are those salts which are pharmaceutically acceptable acid addition salts. Such salts include the chloride, bromide, iodide, sulfate, bisulfate, acetate, salicylate, valerate, laurate, benzoate, phosphate, and the like.

The following examples illustrate the present invention and will enable those skilled in the prior art to practice the present invention.

EXAMPLE 1 2-(phenylhydrazono)-l-adamantaneacetic acid Phenylhydrazine (1 milliliter; 0.01 mole) was added with stirring and at room temperature to a solution of 2- keto-l-adamantaneacetic acid (2.1 grams; 0.01 mole) in 10 milliliters of methanol. The desired 2-(phenylhydrazono)-l-adamantaneacetic acid product appeared as a crystalline precipitate; it was separated by filtration, washed with a few milliliters of ethanol, dried, and finally recrystallized from percent ethanol. The purified 2- (phenylhydrazono)-1-adamantaneacetic' acid product, ca. 2.85 grams, melted at 164-l65 C.

Calc. for C H N O (percent): C, 72.40; H, 7.41; N, 9.39. Found (percent): C, 72.40; H, 7.50; N, 9.44.

EXAMPLE 2 6-phenyl-5,6-diazatetracyclo(7.3'.1.1 0

tetradec-4-en-7-one The 2 (phenylhydrazono) l-adamantaneacetic acid product obtained as reported in Example 1 (2.5 grams thereof) was heated in a preheated oil bath at a temperature around 200 C. for about 45 minutes. The melt, on cooling, solidified and on crystallization from ethanoln-hexane gave 6-phenyl-5,6-diazatetracyclo(7.3.1.1 0) tetradec- 4-en-7-one (2 grams; 9.0 percent), M.P. 7375 C.

Calc. for C H N O (percent): C, 77.11; H, 7.19; N, 10.00. Found (percent): C, 76.99; H, 7.19; N, 9.84.

EXAMPLE 3 6-phenyl-5,6-diazatetracyclo (7.3 l 1 .0) tetradecane To a well-stirred suspension of lithium aluminum hydrido (200 milligrams) in absolute dioxane (l5 milliliters) was added a solution of the 6-phenyl-5,6-diazatetracyclo(7.3.1.l .0' )-tetradec-4en-7-one obtained as reported in Example 2 (1.4 grams; 0.005 mole thereof) in 10 milliliters of absolute dioxane. The mixture was heated to reflux in an oil bath in an atmosphere of nitrogen for about 2 hours. The reaction mixture was then cooled in an ice-water bath and decomposed with dropwise addition of other containing 10 percent methanol by volume; inorganics were centrifuged out and Washed with ether. The filtrate and washings were combined and evaporated under vacuum. The residue was dissolved in ether, filtered, and evaporated alTording a light yellow waxy solid which was crystallized from ethanol-ether to give 6-phenyl-5,6-diazatetracyclo(7.3.l.1 0 )tetradecane,.ca. 1 gram, yield ca. 72 percent, M.P., 7678 C.

Calc. for C H N (percent): C, 80.64; H, 9.00; N, 10.34. Found (percent): C, 80.88; H, 8.88; N, 9.83;

EXAMPLE 4 5,6-diazatetracyclo(7.3.1.1 .0)tetradec-4-en-7-one To a solution of 2-keto-l-adamantaneacetic acid (2 grams; 0.01 mole) in 10' milliliters of absolute ethanol was added hydrazine hydrate of 95 percent purity (0.6 milliliter); the resulting solution. was heated. under reflux on a water bath for about 30 minutes. The solvent was evaporated and the residue was dissolved in ether; the ether solution was Washed with a 5 percent aqueous bicarbonate solution and with water, and then dried over sodium sulfate. The crystalline solid which was left after the removal of ether was recrystallized from ether to give the desired 5,6-diazatetracyclo(7.3.1.1 .0 )tetradec-4- en-7-one product, ca. 1.85 g. (ca. 91 percent), M.P., 156-- 158 C.

Calc. for C H N O (percent): C, 70.56; H, 7.90; N, 13.71. Found (percent): C, 70.40; H, 8.00; N, 13.82.

EXAMPLE 5 5,6-diazatetracyclo 7. 3 1 1 .0 tetradecane A solution of 5,6-diazatetracyclo(7.3.l.1 .0 )-tetradec-4-en-7-one obtained as described in Example 4 (1.02 grams; 0.005 mole thereof) in milliliters of absolute dioxane was mixed with a stirred suspension of 0.3 gram of lithium aluminum hydride in 10 milliliters of absolute dioxane. The mixture was heated under reflux in a nitrogen atmosphere for 26 hours. The reaction mixture was then decomposed and worked up as described hereinbelow in Example 7, giving a gum, which was purified through chromatography in a methylene dichloride solution over a column (17 x 0.5 cm.) of neutral alumina, eluting the column with methylene dichloride. On removal of solvent, the desired 5,6-diazatetracyclo(7.3.1.1 .O )tetradecane product was obtained as a colorless gum (0.56 gram; 58 percent) which was dissolved in dry ether; its hydrochloride was precipitated by dropwise addition of ethanolic HCl; the precipitate was filtered, washed with ether and crystallized from 2-propanol, ca. 0.4 gram (ca. 36 percent), M.P., 144l46 C.

Calc. for C H N -HCI (percent): C, 63.02; H, 9.24; N, 12.25. Found (percent): C, 63.70; H, 9.10; N, 12.35.

EXAMPLE 6 6-methy1-5,6-diazatetracyclo(7.3.1.1 .0 )tetradec- 4-en-7-one A solution of 2-keto-l-adamantaneacetic acid (2.1 grams; 0.01 mole) in 10 milliliters ethanol was treated with methylhydrazine (0.5 gram; 0.01 mole) and the mixture was heated under reflux temperature for about 30 minutes. On cooling, the desired 6-methyl-5,6-diazatetracyclo( 7.3.1.1 .0 )tetradec-4-en-7-one product appeared as a crystalline precipitate; it was collected on a filter, washed with a little cold ethanl, dried (2 grams) and recrystallized from petroleum ether (60-80") (1.9 grams; 90 percent), M.P. 55-57 C.

Calc. for C H N O (percent): C, 71.53; H, 8.31; N, 12.83. Found (percent): C, 71.47; H, 8.21; N, 12.80.

EXAMPLE 7 6-methyl-5,6-diazatetracyclo(7.3.1.1 .0 )tetradecane A solution of 6 methyl-5,6-diazatetracyclo(7.3.1.1" .0 )tetradec-4-en-7-one prepared as described in Example 6 (1.64 grams; 0.0075 mole) in 10 milliliters of absolute dioxane was added to a well-stirred suspension of lithium hydride (300 milligrams) in absolute dioxane milliliters); the stirring was continued under nitrogen and at reflux temperature on an oil bath for 2 hours. The mixture was then cooled in an ice bath and decomposed with ether/methanol (9:1 by volume), precipitated in organics being filtered out by centrifuging and subsequently washed with ether. The combined filtrate and wash were evaporated under vacuum to obtain the desired 6-methyl-5,6- diazatetracyclo(7.3.1.1 .0 )tetradecane product as a residue. This product was dissolved in ether and filtered. The solution on evaporation yielded an oil (1.5 grams) which was distilled: 100102/2 mm., to give purified product (ca. 1.3 grams; 84 percent yield).

Calc. for C H N (percent): C, 75.68; H, 10.75; N, 13.57. Found (percent): C, 76.21; H, 10.83; N, 12.93.

Hydrochloride: M.P. 232234 C. (sub) (ethanol/petroleum ether).

Calc. for C H N -HCl (percent): C, 64.31; H, 9.45; N, 11.54 Found (percent): C, 64.45; H, 9.10; N, 11.55.

6 EXAMPLE 8 6-(p-chlorophenyl)-5,6-diazatetracyclo(7.3.1.1 0 tetradec-4-en-7-one To a solution of 2-ket0-l-adamantaneacetic acid (1 gram; 0.005 mole) in 6 milliliters of ethanol was added a solution of (p-chlorophenyl)hydrazine hydrochloride (0.9 gram; 0.005 mole) in 15 milliliters of 50 percent aqueous ethanol. The mixture was heated on a water bath for 15 minutes; the desired 6-(p-chlorophenyl)-5,6-diazatetracyclo(7.3.11 .0 )tetradec-4-en-7-one product separated as a crystalline substance when the reaction mixture was cooled. This product was separated by filtration, washed with 95 percent ethanol, and dried (1.5 grams; ca. 95 percent), M.P. 158-160 C.; recrystallization from ethanol afforded flakes, M.P. 164166 C.

Calc. for C H N OCl (percent): C, 68.67; H, 6.10; N, 8.90; Cl, 11.27. Found (percent): C, 68.42; H, 6.31; N, 9.01; Cl, 11.11.

EXAMPLE 9 2-( (p-nitrophenyl)hydrazono)-1-adamantaneacetic acid To a solution of 2-keto-l-adamantaneacetic acid (2.1 grams; 0.01 mole) in 10 milliliters of methanol was added a solution of (p-nitrophenyl)hydrazine (1.54 grams; 0.01 mole) in glacial acetic acid-water mixture (1:2 by volume). The desired 2-((p-nitrophenyl)hydrazono)-1-adamantaneacetic acid product precipitated and was filtered, washed with ethanol, dried, and crystallized from ethanolglacial acetic acid, ca. 3.3 grams; M.P., 204206 C.

Calc. for C H N O (percent): C, 63.00; H, 6.14; N, 12.24. Found (percent): C, 63.18; H, 5.90; N, 12.13.

EXAMPLE 10 6-(p-nitrophenyl)-5,6-diazatetracyclo(7.3.11 .0 tetradec-4-en-7-one The 2 ((p-nitrophenyl)hydrazono)-1adamantaneacetic acid product obtained as reported in Example 9 (2.5 grams thereof) was heated in a preheated oil bath (around 215 C.) for 20 minutes, incoming moisture being prevented by a CaCl guard tube. The brownish melt, when cold, turned into a solid mass, which was crystallized from ethanol, to give the desired 6-(p-nitrophenyl)-5,6-diazatetracycl0(7.3.11 .0 )tetradec 4 en-7-one (ca. 2.1 grams; 89 percent) M.P. 173-175" C.

Calc. for C H N O (percent): C, 66.44; H, 5.89; N, 12.91. Found (percent): C, 66.33; H, 5.96; N, 12.62.

EXAMPLE 11 6-(Z-hydroxyethyl)-5,6-diazatetracyclo (7.3.1.1 .0

tetradeco-4-en-7-one 2-keto-l-adamantaneacetic acid (1 gram; 0.005 mole) was dissolved in 15 milliliters of ethanol; to the solution was added (2-hydroxyethyl)hydrazine (0.4 gram; 0.005 mole) and the mixture was heated under reflux for 1 hour and then evaporated under vacuum; the resulting solid gurn, the desired 6-(2-hydroxyethyl)-5,6-diazatetracyclo- 7.3.1.1 .0 )tetradec-4-en-7-one product, was crystallized from benzene/petroleum ether (60-80); (ca. 1 gram; percent), M.P. 9496 C.

Calc. for C H N O (percent): C, 67.5; H, 8.5; N, 11.3. Found (percent): C, 67.9; H, 8.2; N, 11.4.

Other representative products of the present invention are prepared in accordance with the foregoing examples and teachings. Such compounds include the following:

EXAMPLES 12-14 8-methyl-5,6-diazatetracyc10 (7.3 .1 .l .0 tetradec-4- en-7-one, and its corresponding reduced product, 8-methyl- 5,6-diabatetracyc1o(7.3.1.1. .O )tetradecane, are prepared from 2-keto-a-methyl-l-adamantaneacetic acid and hydrazine through the intermediate 2-hydrazono-a-methyl-l-adamantaneacetic acid.

I ,zon'o);1-adamantaneacetic acid. 1

, phenyl)hydrazono)-l-adarnantaneacetic acid.

'azatetracyclo (7.3 .1 .1 .0 )tetradecane,

7 I hydrazono)-3,,5,7 trimethyl-Ladamantaneacetic acid EXA L s sal? V powders, oral solutions or 6-m-t'o1 1-5,s-diaz tetracycroms.iwo )terraces-a ien pared from '2 keto-l-adamantaneacetic acid and m tolyl i Z-(m-tolylhydraf hydrazine; through the intermediate EXAM LES {158401 I s ethyl ;2,4 dinitriophenyl) 5,61 diazate say 7 clo(7.3.j1'.1 .0 )tetradecF4 en-Z-oneg and its corresponding reduced product,i 8- ethyl-6-(2,4 dinitrophenyl) j (2,4-dinitrphenyl)hydrazine, through the intermediate taneacetic acid.

' EXAMPLES '21-,23

'8 n butyl 6 (o-chlorophenyl) 5,6 diazetet'ra ,cyclo(7;3.l,l3; .0t )tetradecefl-enfl-one, andfitsporre-ispondin g-reduced. product,-8rn 'butyl6 torchlorophey 5,6-diazatetraeyclo(7.3. 1.1 .0 )tetradecane, are ,pte- 1 pared from 2-keto-ix-n-butyl'-l-adamantaneacetic acid and, V (o-chlorophenyl)hydrazine, through the intermediate 2- ((0 chlorophenyl)hydrazono)-o-n-butyl-I-adamantane acetic acid.. a V 1 a i EXAMPLES24-26 a 6 (2,4,5 trichlorophenyl) 5,6 diazatetracyclo- (7.3.11 .0 )tetradec-4-en-7-one, and its corresponding reduced product 6-(2,4,S-trichlorophenyl)-5,6-diazatetra-. cycl0(7.3.11 1 .0)tetradecane, are prepared from 2-] formulated .in a suitable injectable liquid; The exact supplied to; the'animal being treated; I In. general, an'anti injtiammatory effect rates oftromd to 250 milligrams; or morepe'r kilogram A of animal ,bodyfweight, 'depending uponthe particular, compound chosen, mode of application and: the like; Such, t5,d-diazatetraoycloflfi;l13 0 )tetradecansi are311 m- 1 dosage" can be: adminismricd time Olin (Several I pared from Z-keto-dethyl l-adarnantaneacetic acid and concentration of the" active agent in such formulation is Ynot critical it being necessary onlyvthat an appropriate, dosage of the active agent, as hereinafter set forth, be j isffachieved at administrations overa given period of time' such as daily. r

V In implementing theCNSdepressant activity ofcth'e; productsof the present-invention, theproducts generally give good resultsat dosages of froml00-400 mg./kg;when

7 administered intraperitoneally. Higher dosages can cause undesirable side etfectsineluding" toxic effects, and. are therefore generally'to: be avoided. Lesser amountgof.

course, can be used and are often protested inorderto I, achieve highly specific response.

' The utilityof the productsof the'preseut invention is illustrated by the following examples. 7

EXAMPLES 36-40 Various representative products of ,the present inven tion were evaluated for anti-inflammatory activity in acketo-l-adamantaneacetic acidand (2,4, 5-trichlorophenyl) hydrazine, through'the intermediate 2-(('2',4,5 trichloro- EXAMPLES 27-29 i group was orally given a saline solution'onlysto serve as V 6 4 (2 hydroxy 1 methylethyl) 5,6 diazatetra-C I cyclo(7.3.LI .0 )tetradec+4-en-7-one, and its corre-* sponding reduced product, 6-(Z-hydroxy-l-methylethyD- 5,6-diazatetracyclo(7.3.1.1 3.0 9.)tetradecane, 7 are pre: pared 'from ,2-keto:I-adamantaneacetic acid. and (2-hydroxy-l-methylethyDhydrazine, through the intermediate 2 (,(2 hydroxy -'1 methylethynhydrazono} adamanw;

taneacetic acid. w 1

a EXAMPLES 30-32 r (7.3.1.1 .O )tetradec-4-en-7 one, and its, correspond ing reduced product, 6-'sec-butyl-lr,3,ll-trimethyLSfi-diare prepared from 2-keto-3,5,7trimethyl-l adamantaneacetic acid;v and sec-butylhydrazine, through the intermediate 2-(sec-buty1- EXAMPLES 33451 7 6 -(p 5 bromophenyl) '-1,3%- diisopropyl- '5 ,6 d1-- azatetracyc'lo("[.31.1 0 tetradecl enii-lone', and; its

a control group. The degree of reduction: of swelling in both the control rats and the treated ratswas thereafter, determined. The precise amounts of the various com" pounds administered, as well as the percent reduction of swelling observed, is set forth in the following table.

, l s a 7 in each of reduction Compound beingevaluated- 5,6-diazatetracyclm(73.;11 3 .05 5,6.-diazatetracycl {7.3.1.1 .0 )-tetradec 4- en7 one 100 44. 8

o' m'ethyl 5,o-diaZatetraQyclQGB I 4 tetradecane monohydroohloride- 190 fi-phenyl-5,6-diazatetracyclo(7.3.1.1 9 .0 31 tetradecane a... -c... 100; 50. 7

G-(p-nitropheny1(-5,6-diazatetrs .0 )tetradec-den-7-one. 25 V 38. 0 6-methyl5,6@diazatetracyclo( tetradac4-em7-one-..--

XA PLEssY-sa 1 In otherrepresentative procedures, groups of mice, two mice per group, wereemployed in the evaluation. of var'i-J I ous adamantano-pyri'dazine products'offthepresent; i'ncorresponding. reduced product, '6'-(p-br-ornophenyl}-1,3-diisopropyl-5,6 diazatetracyclo(7.3.1.1 .0 )tetradecane,

are prepared from 2-keto-3,5-diisopropyl'- adamantaneacetic aicd and (p-bromophenyl)hydrazine. through the intermediate 2-((p-bromophenyl)hydrazono)-3,5-di- I isopropyl-l-adamantaneacetic acid.

The adamantanopyridazine products of thepresent 111- vention are useful as anti-inflammatoryagents in various inflammatory.states, including arthritic conditions, and as including oral, sub-cutaneous,'and the'like. Generally, though, .oral', administration is'rnost' convenient and is l therefore, preferred. The compounds can be formulated to facilitate the administration of the present active agents. Thus, the compounds can be formulated in liquid or :solid 7 formulations, suchwas tablets, pills, capsules, granules,

; CNSskPr esst i f ras msle is ss ate s firf ier-excitement. They are'effective'wheli' adrninlsteiiuigto r warm-blooded animals by any :of the common routes,

vention. Each group was administered one oflthe candi date compounds and all groups were, thereafter observed in accordance with standardized test procedures'for the changed response of the. mice in. tests for general activity,

irritability, rate of respiration, and other'indicators of CNS depression. In these tests, each of the compounds listed below showed CNS depression, at the dosage set forth and in the modeof administration,cidentifieda'In' this following table, i-.p. is employed as an abbreviation for the termintraperitoncall 7 a a 7 adminis in Name of compound I tration nag/kg.)

. (S-(p-chlorophenyl)-5,fi-diamtetracyclo(7.3.1.- i.p c..." 13$;.0 ,9) tetradecA-en-7-oue. 1 a W B-(Z hydroxyethyl)-5,fi=diazatetracyelo (7.31. i 206 1 .0 )tetradec-4-en-7-one. 400 t 6-methy1-5,6-diazatetracyclo (7 .3.1.l .O 400 tetradocane hydrochloride.

suspensions,;and the 1'ikc.,Also, ,7 c 'where'tthecompound serving active agent is to. head ministered by a parenteral route, the compound can be P ercent two doses ofswelling.. 7 48.9."

Mode of V possess are prepared by the oxidation, for example, with an auraline permanganate solution, of the corresponding 2-hydroxyl-adamautanethanol:

-01: \l/ R In a representative operation, there was prepared a wellstirred suspension of a 2-hydroxy-l-adamantanethanol (3 grams) in 6.6 milliliters of 20 percent aqueous solution of sodium hydroxide. To this suspension, there was gradually added a solution of potassium permanganate (4.2 grams) in 85 milliliters of water. After this addition, a deep green color persisted, and another batch of permangate solution (4.2 grams in 85 milliliters of water) was added gradually and the reaction mixture was mildly heated on a steambath for about 3 hours and then kept overnight at ordinary room temperature. The solution was filtered from manganese dioxide and the precipitate washed with water. The combined filtrate and wash were extracted with ether. The aqueous layer was then acidified with dilute sulfuric acid and the preciptiated acid was extracted into ether. The ether solution was washed with water, dried with magnesium sulfate, and evaporated under vacuum. The resulting solid was crystallized from a mixture of ether and n-hexane to give the desired 2- keto-l-adamantaneacetic acid product (2.5 grams; 80 percent), M.P., 145146 C. The acid was further characterized through its oxime, M.P., 153155 C., its dinitrophenylhydrazone, M.P., 258260 C., and its semicarbazo, M.P., 222-224 C.

Other of the 2-keto-l-adamantaneacetic acid starting materials are prepared in similar procedures. All of the necessary 2 hydroxyl-l-adamantanethanol compounds are prepared in the same manner described for the preparation of 2 hydroxyl-l-adamantaneethanol in pending U.S. application for Letters Patent Ser. No. 675,037, filed Oct. 13, 1967.

We claim:

1. The comopund of the formula wherein R represents hydrogen or loweralkyl of C -C both inclusive, the sum of the number of carbon atoms in all three R groups being not greater than 6; R represents hydrogen or straight-chain loweralky 10f C -C and R represents hydrogen, loweralkyl of C -C hydroxyloweralkyl of C -C phenyl, or substituted phenyl of the formula wherein R' represents bromo, chloro, or methyl; m represents 0-3, both inclusive; and n represents 0-2, both inclusive, the sum of m and n being an integer of from 1-3, both inclusive.

2. The compound of claim 1 which is 2- (phenylhydrazono)-1-adamantaneacetic acid.

3. The compound of claim 1 which is 2-((p-nitrophen yl)hydrazono)-l-adamantaneacetic acid.

No references cited.

LORRAINE A. WEINBERGER, Primary Examiner R. GERSTL, Assistant Examiner U.S. C1. X.R. 260-514 G, 518 A 

